Success Metrics

Clinical Success Rate
91.4%

Based on 32 completed trials

Completion Rate
91%(32/35)
Active Trials
11(18%)
Results Posted
34%(11 trials)
Terminated
3(5%)

Phase Distribution

Ph phase_2
14
23%
Ph not_applicable
11
18%
Ph phase_1
2
3%
Ph phase_3
19
31%
Ph phase_4
9
15%

Phase Distribution

2

Early Stage

14

Mid Stage

28

Late Stage

Phase Distribution55 total trials
Phase 1Safety & dosage
2(3.6%)
Phase 2Efficacy & side effects
14(25.5%)
Phase 3Large-scale testing
19(34.5%)
Phase 4Post-market surveillance
9(16.4%)
N/ANon-phased studies
11(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.4%

32 of 35 finished

Non-Completion Rate

8.6%

3 ended early

Currently Active

11

trials recruiting

Total Trials

61

all time

Status Distribution
Active(11)
Completed(32)
Terminated(3)
Other(15)

Detailed Status

Completed32
unknown15
Recruiting7
Active, not recruiting4
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
61
Active
11
Success Rate
91.4%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (3.6%)
Phase 214 (25.5%)
Phase 319 (34.5%)
Phase 49 (16.4%)
N/A11 (20.0%)

Trials by Status

terminated35%
unknown1525%
active_not_recruiting47%
completed3252%
recruiting711%

Recent Activity

Clinical Trials (61)

Showing 20 of 61 trialsScroll for more
NCT07816562Phase 3

Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST)

Recruiting
NCT02005887Phase 2

TRial on the Endocrine Activity of Neoadjuvant Degarelix

Completed
NCT00066690Phase 3

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Completed
NCT04423211Phase 3

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Recruiting
NCT05050084Phase 3

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Active Not Recruiting
NCT04513717Phase 3

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Active Not Recruiting
NCT07455903Phase 2

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Recruiting
NCT04484818Phase 3

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Active Not Recruiting
NCT06378866Phase 2

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

Recruiting
NCT05982093Phase 2

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Recruiting
NCT05896566Phase 2

A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Completed
NCT00066703Phase 3

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Completed
NCT05701007

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed
NCT03678025Phase 3

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Recruiting
NCT00667069Phase 3

Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer

Completed
NCT02278185Phase 2

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

Completed
NCT02685397Phase 2

Management of Castration-Resistant Prostate Cancer with Oligometastases

Active Not Recruiting
NCT02366494

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Completed
NCT00702520

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)

Completed
NCT06581679Not Applicable

Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer

Completed

Drug Details

Intervention Type
DRUG
Total Trials
61